Q-omics provides the consensus-scored UGGT2 profile across patient tissues and cancer cell-line models. UGGT2 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, UGGT2 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, UGGT2 RNA expression shows 20,011 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight LUSC, HNSC, and UVM as cancer lineages where UGGT2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UGGT2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UGGT2 survival associations across molecular data types. UGGT2 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (9) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UGGT2 RNA expression–survival associations across cancer types. High UGGT2 expression shows unfavorable associations in LUSC, UVM, LIHC, HNSC and STAD, but favorable associations in UCS. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify LUSC as the clearest survival context for UGGT2 RNA expression.
This table summarizes UGGT2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for UGGT2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UGGT2 shows higher tumor expression in HNSC, COAD, LIHC, BLCA, LUAD and READ. The HNSC box plot shows higher UGGT2 RNA expression in tumor versus normal tissue (log2 FC = +0.976, t-test p < 0.001).
This table shows molecular features associated with UGGT2 in patient tissues and cancer cell lines. In patient samples, UGGT2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, UGGT2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BONE.
